Miproxifene phosphate

Miproxifene phosphate is a selective estrogen receptor modulator (SERM) that was under development by Eisai but was never marketed. It is a phosphate ester of miproxifene, which, similarly to tamoxifen, is a triphenylethylene derivative.

Pharmacology

Miproxifene phosphate acts as a SERM, or selective estrogen receptor modulator. This means it has the ability to act as an agonist or antagonist to the estrogen receptor, depending on the specific tissue type. This selective action allows it to have beneficial effects in certain tissues, such as bone, while potentially avoiding the negative effects of estrogen in other tissues, such as the breast and uterus.

Development

Miproxifene phosphate was developed by the pharmaceutical company Eisai. Despite its potential benefits, the drug was never marketed. The reasons for this are not publicly known.

Chemistry

Miproxifene phosphate is a phosphate ester of miproxifene. Miproxifene itself is a derivative of triphenylethylene, a compound that also forms the basis for the well-known SERM tamoxifen.

See also

• Selective estrogen receptor modulator
• Eisai (company)
• Tamoxifen
• Triphenylethylene

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a medical stub. You can help WikiMD by expanding it!